Last Updated : October 30, 2023
Details
Generic Name:
atogepant
Project Status:
Pending
Therapeutic Area:
Migraine, prevention
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Qulipta
Project Line:
Reimbursement Review
Project Number:
SR0817-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the prevention of chronic migraine in adults with 15 headache days per month (among which 8 days are considered to be migraine days) and who have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The prevention of migraine in adults.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 30, 2023